Promoting HPV Vaccination Among Young Adults in Texas

NCT05057312 | Active Not Recruiting

• 3 other identifiers: 2020-1142R01CA248216NCI-2021-09416
• Study Type: interventional
• Target: 1,200
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial studies how to improve the human papillomavirus (HPV) vaccination rate in young adults in Texas. This trial aims to learn more about how researchers and health care providers can increase HPV vaccination among college students.

Conditions

Human Papillomavirus Infection

Outcome Measures

Primary Outcomes (2)

• Rate of human papillomavirus (HPV) vaccination initiation

  At 3 months

• Rate of HPV vaccination completion

  At 9 months

Study Arms (6)

Group I (standard CDC information)

ACTIVE COMPARATOR

Participants receive standard CDC information about HPV vaccination.

Other: Informational Intervention; Other: Interview; Other: Questionnaire Administration

Group II (video narratives)

EXPERIMENTAL

Participants receive video narratives about HPV vaccination.

Other: Informational Intervention; Other: Interview; Other: Questionnaire Administration

Group III (written narratives)

EXPERIMENTAL

Participants receive written narratives about HPV vaccination.

Other: Informational Intervention; Other: Interview; Other: Questionnaire Administration

Group IV (enhanced access to vaccine, CDC information)

EXPERIMENTAL

Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.

Other: Enhancing Accessibility to Health Care; Other: Informational Intervention; Other: Interview; Other: Questionnaire Administration

Group V (enhanced access to vaccine, video narratives)

EXPERIMENTAL

Participants receive enhanced access to vaccination and video narratives about HPV vaccination.

Other: Enhancing Accessibility to Health Care; Other: Informational Intervention; Other: Interview; Other: Questionnaire Administration

Group VI (enhanced access to vaccine, written narratives)

EXPERIMENTAL

Participants receive enhanced access to vaccination and written narratives about HPV vaccination.

Other: Enhancing Accessibility to Health Care; Other: Informational Intervention; Other: Interview; Other: Questionnaire Administration

Interventions

Enhancing Accessibility to Health Care OTHER

Receive enhanced access to vaccination

Group IV (enhanced access to vaccine, CDC information); Group V (enhanced access to vaccine, video narratives); Group VI (enhanced access to vaccine, written narratives)

Informational Intervention OTHER

Receive standard CDC information

Group I (standard CDC information); Group IV (enhanced access to vaccine, CDC information)

Interview OTHER

Ancillary studies

Group I (standard CDC information); Group II (video narratives); Group III (written narratives); Group IV (enhanced access to vaccine, CDC information); Group V (enhanced access to vaccine, video narratives); Group VI (enhanced access to vaccine, written narratives)

Questionnaire Administration OTHER

Ancillary studies

Group I (standard CDC information); Group II (video narratives); Group III (written narratives); Group IV (enhanced access to vaccine, CDC information); Group V (enhanced access to vaccine, video narratives); Group VI (enhanced access to vaccine, written narratives)

Eligibility Criteria

• Age: 18 Years - 26 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up to 26 years of age and the fact that individuals 18 years and older can consent by themselves for on-site vaccination
• Ability to read and understand English
• Self-identification as not yet having received any HPV vaccine injections. Self-identification is justified because it is safe to be vaccinated again, which could happen if a previously vaccinated person forgets their vaccination. Furthermore, in a person previously vaccinated with an older version of the vaccine, which targeted fewer HPV types, receiving the newer version would be advantageous and not cause any harm. Alternatives to self-identification, such as obtaining medical records from doctors' offices, would be very challenging for young adults, especially for those who do not remember when and where they might have received vaccination
• Access to a smart phone, tablet or computer that is connected to the internet
• Current enrollment in one of the participating schools with an anticipated continuous enrollment of at least 9 months

You may not qualify if:

• Being pregnant
• Having a life-threatening allergy to any component of the HPV vaccine

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Publications (1)

• Lu Q, Dawkins-Moultin L, Cho D, Tan NQP, Hopfer S, Li Y, Ramondetta L, Xu Y, Lun D, Chen M. A multilevel intervention to promote HPV vaccination among young adults in Texas: protocol for a randomized controlled trial. BMC Public Health. 2024 Jun 5;24(1):1506. doi: 10.1186/s12889-024-18828-9.

  PMID: 38840086 DERIVED

MeSH Terms

Conditions

Papillomavirus Infections

Interventions

Interviews as Topic

Condition Hierarchy (Ancestors)

Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Communicable Diseases; Infections; DNA Virus Infections; Virus Diseases; Tumor Virus Infections; Genital Diseases; Urogenital Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Qian Lu, MD,PHD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 25, 2021
• First Posted: September 27, 2021
• Study Start: July 26, 2021
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): July 31, 2026
• Last Updated: January 21, 2026

Record last verified: 2026-01

Locations

US (1)